OpenAI, PerturbAI, and Scripps Research just showed off a distributed swarm of thousands of GPT-Rosalind agents analyzing CRISPR data from millions of mouse brain cells in 32 minutes—a task that typically takes humans months to a year. The agents combed literature to surface fresh leads for neurodegenerative diseases like Parkinson's, showing how parallel AI can turn massive biological datasets into testable lab hypotheses.
OpenAI just acquired Orchestra Bio to combine agentic workflows with its Rosalind life sciences suite. The integration is designed to let AI handle coordination hiccups across complex trials and compress the grueling 10-to-15-year drug development cycle for partners like Novo Nordisk and Moderna.
OpenAI just launched the Rosalind Academic Plan, offering eligible U.S. university labs up to 30 free seats for 12 months to access GPT-Rosalind and its life-sciences workbench. Labs get specialized reasoning tools for drug discovery and genomics without their data being used for training. Why it matters: Frontier bio-AI brings huge potential alongside real biosafety concerns, so OpenAI is lowering the cost barrier for vetted academic researchers first, though API access remains excluded.
OpenAI just committed $17 million in resources to the U.S. Department of Energy’s Genesis Mission, aiming to double national research productivity within a decade. The pledge includes $4 million in Codex access for 2,000 scientists, targeted support for high-temperature superconductors, and deploying reasoning models on the Venado supercomputer. Why it matters: OpenAI is embedding frontier models directly into federal scientific infrastructure to compress decades of research into years.
OpenAI just published its National Security Principles, outlining hard boundaries for how governments and defense agencies can deploy its models. The guidelines explicitly ban AI use for mass domestic surveillance, autonomous weapons direction, and high-stakes automated decisions, applying directly to its work with defense agencies and nine allied nations.
OpenAI just updated GPT-Rosalind, its specialized model series for enterprise life sciences research, baking in GPT-5.5's agentic coding and tool-calling skills. The new model beats GPT-5.5 on wet lab troubleshooting, medicinal chemistry, and genomics while burning up to 31% fewer tokens, aiming to slash the time scientists spend connecting dry-lab data to wet-lab experiments.
OpenAI just launched Rosalind Biodefense, granting vetted developers and select government partners access to GPT-Rosalind, its frontier reasoning model built for life sciences. The sponsored initiative aims to accelerate pandemic preparedness, threat detection, and medical countermeasures alongside collaborators like Lawrence Livermore National Laboratory.
OpenAI's former chief product officer Kevin Weil just left the company after two years, as OpenAI sunsets its Prism science workspace and rolls the 10-person team into Codex. The move comes alongside departures from two other executives, as the company trims products to turn Codex into an "everything app" ahead of an IPO.
OpenAI just unveiled GPT-Rosalind, a frontier reasoning model purpose-built for biology, genomics, and drug discovery. It beats GPT-5.4 on six of 11 LABBench2 tasks and landed in the 95th percentile against human experts on RNA sequence prediction. While model access requires trusted vetting, OpenAI also dropped a free research plugin on GitHub.
